Background: Previously, some differences between non-radiographic and radiographic axial spondyloarthritis (axSpA) -such as a higher prevalence of females and lower level of acute phase reactants in non-radiographic axSpA (nr-axSpA) -have been reported in national observational studies, mostly from Europe. Objectives: To compare demographic and clinical characteristics of patients (pts) with nr-axSpA and radiographic axSpA (ankylosing spondylitis, AS) in a large multinational cohort of pts with recently diagnosed axSpA. Methods: PROOF is a prospective observational study evaluating clinical and radiographic outcomes in axSpA pts in rheumatology clinical practice in 29 countries. Pts with axSpA fulfilling ASAS classification criteria were eligible if diagnosed ≤1 year prior to study enrolment. Investigator's confidence with the diagnosis of axSpA was ascertained on a numeric rating scale (NRS 0-10) at enrolment and end of follow-up. At baseline, demographic and clinical data related to the diagnosis, disease activity, quality of life and work productivity, as well as conventional radiographs of the sacroiliac joints were collected. Classification as nr-axSpA or AS was based on the results of the assessment of sacroiliac radiographs. Available radiographs were assessed first by a local reader and then by a central reader according to the grading system of the modified New York criteria. In the case of a disagreement in the classification (nr-axSpA or AS), the radiograph was evaluated by the 2nd central reader, who was blinded to the previous assessments and the final classification was made based on the decision of 2 out of 3 readers. Results: Of the 2126 pts enrolled in PROOF, 1281 (60.3%) pts were classified as AS and 845 (39.7%) as nr-axSpA according to investigators. The confidence with the diagnosis of axSpA was 8.7±1.8. The final classification according to the central assessment of sacroiliac radiographs was confirmed in1583 pts included in this analysis. A total of 987 pts (62.3%) were classified as AS and 596 (37.7%) as nr-axSpA. AS pts expectedly had longer symptom duration, more frequently had elevated and higher CRP and were more often male and treated with TNF inhibitors (Table) . In addition, HLA-B27 positivity was more frequent among AS pts, while pts with nr-axSpA had a significantly higher prevalence of enthesitis, psoriasis, and inflammatory bowel disease (IBD). The prevalence of other SpA features was comparable between the two subgroups of axSpA. Mostly, ptreported outcomes reflecting burden of disease were comparable between the two subgroups, but BASDAI was significantly higher in the nr-axSpA subgroup (Table) . Conclusions: There were a few differences between nr-axSpA and AS pts in the PROOF cohort. The clinical constellation of female sex, low CRP, enthesitis, psoriasis, and IBD in nr-axSpA pts appears to reflect a phenotype less prone to structural damage in the sacroiliac joints. However, the clinical burden of disease was comparable between the two subgroups of axSpA. Background: It is reported that subclinic intestinal inflammation may occur in Ankylosing spondylitis (AS) patients, besides, using NSAIDs cause peptic and duedenal ulcers. %50-60 of AS patients have asymptomatic ileal and colonic mucosal inflammation. It is reported that inflammatory bowel disease (IBD) is found in 5-10% of AS patients and 4-10% of IBD patients have concomittant findings with AS. These conditions may cause iron deficiency anemia (IDA). Objectives: It is well known that chronic disease anemia is a frequent finding in AS patients. But there is no study in the literature about relationship between AS patients and IDA. In this particular study we aimed to asses frequency of IDA in AS patients and to investigate the etiologies of IDA. Methods: Ninety four consecutive AS patients who meet 2012 ASAS/EULAR criteria, who were followed Çukurova University Romatology Clinic, were icluded. We investigated the etiologies of IDA in anemic patients. Twenty six AS patients were diagnosed as IDA. Twenty six patients without anemia were assigned as a control group. Hepcidin, soluble transferrin receptor1 (sTfR1) and anemia parameters were tested in both groups. Findings were anayzed with SPSS version 23. Results: Twenty six of 94 AS patients were diagnosed as IDA (%27). Frequency of IDA in our AS patients was higher when compared to the IDA prevalence in the society (%1-2). Endoscopy and colonoscopy were performed for searching etiology of IDA. Mucosal inflammation was found in 62% of patients by endoscopy and 11% of patients by colonoscopy. One patient was diagnosed as Crohn's disease and one patient was diagnosed as Coeliac disease histopathologically. Hepcidin was found to be significantly lower in IDA patients (p<0.01). We found sTfR1 levels significantly higher in IDA patients (p<0,01). BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and sedimentation values were found to be higher in IDA patients statistically (p<0.01and p=0.01 respectively). Although we found C-reactive protein (CRP) values were higher when compared to the non-anemic patients; however it was not statistically significant (p>0.05).
Conclusions:
We found higher frequency of IDA when compared to the normal population. We found that AS was more active in patients who were diagnosed as IDA. We suggest that AS activitiy may cause mucosal inflammation and subsequently may result as IDA. Also we found that mucosal inflammation in AS patients is not related to NSAIDs because there was no difference about mucosal lesions between NSAID taking and non-NSAID taking group. No study was met in the literature concerning AS and IDA. Our findings should be supported by further studies. References: [1] Background: Chronic back pain is a prominent symptom in Spondyloarthritis (SpA), and an important contributor to diminished quality of life (1, 2) . Chronic pain can develop in intensity, become more spread, and progress to chronic widespread pain (2) . Mechanisms for this are yet inconsistent (3), and in SpA, knowledge of progression to chronic widespread pain (CWP) is lacking. Objectives: To study the development of CWP in patients with SpA, and to identify risk factors for development and persistence of CWP. Methods: A cohort study with baseline and 2.5-year follow-up postal surveys. 644 patients (47% women) with ankylosing spondylitis (AS) and undifferentiated spondyloarthritis (SpA) answered both surveys, and were categorized as no chronic pain (NCP), chronic regional pain (CRP), and CWP. Logistic regression analyses, with CWP as the main outcome were performed. Due to multicollinearity, each risk factor candidate (disease duration, BMI, smoking, and different patient-reported outcome measures; PROMs) were analysed in separate logistic regression models together with a base model (age, sex, and SpA-subgroup). Results: At follow-up, prevalence estimates for NCP, CRP and CWP were similar to those at baseline, but 38% of the patients had transitioned between the groups. A large group, 72% of the patients with initial CWP, also reported persistent CWP at follow-up (Figure) . Risk factors (OR and 95% CI) for development of CWP from initial NCP/CRP were more pain regions (1.36; 1.20-1.53), pain intensity (1.35; 1.20-1.52), fatigue (1.25; 1.13-1.38), global health (1.35; 1.19-1.54), EQ-5D (0.05; 0.01 -0.19), BASDAI (1.25; 1.07 -1.45), BASFI (1.32; 1.16 -1.50), ASES pain (0.97; 0.96 -0.99), ASES symtom (0.98; 0.97 -0.99), and HADb (1.10; 1.02 -1.19). The risk factors for persistent CWP, compared to patients transitioning to NCP or CRP, were similar to those predicting development of CWP, but in addition, also higher age (1.02; 1.00-1.04), and female sex (1.82; 1.06-3.10), predicted the outcome.
The total prevalence of CWP did not change over the study-period, although a substantial transition between the pain-groups were found. More pain regions, higher pain intensity, fatigue and worse self-reported health predicted the development into CWP, and persistent CWP. Also, higher age and female sex were risk factors for persistent CWP in SpA. Special attention in patients who report increased pain and related symtoms is essential, to early identify the development of CWP in patients with SpA.
